Skip to main content
International
Ask us anything:
  • About
        • About We challenge convention so healthy can be possible
        • Our Story
          • Amneal at-a-glance
          • Our Founders
          • Our Milestones
        • Our Purpose & Commitments
        • Our Culture
          • Rise, Lead, Succeed
        • Our Leadership
          • Executive Leadership
          • Board of Directors
        • Our Locations
        • Responsibility
          • The Amneal Patient Assistance Programs
          • Product Donations
          • National & Local Philanthropy
          • Compliance and Ethics
        • Patient Community Connections
          • Our Commitment to Parkinson's
        • Awards & Recognition
  • Products
        • Products We create essential medicines
        • Our Portfolio
          • Biosciences
          • Generic Products
          • Specialty Products
          • Product Catalog
        • Quality
        • Drug Safety
          • Adverse Event Reporting
          • Medical Inquiries
          • Product Complaints
        • Operations
  • Research & Development
        • Research & Development We invest significantly in new product development
        • Generics R&D
        • Specialty R&D
          • Drug Delivery Technologies
        • Product Partnering
  • Investors
        • Investors Become an Informed Investor
  • News
  • Careers
        • Careers Help make healthy possible
        • Total Rewards
        • Search Our Career Opportunities
  • Contact
  • Customer Login
Amneal Pharmaceuticals
  • Investor Relations
  • Financial Reports
    • SEC Filings
    • Annual Reports
    • Quarterly & Other Reports
  • Events & Presentations
  • Stock Information
  • Corporate Governance
    • Policies
    • Executive Officers & Directors
    • Board Committees
  • Investor Resources
    • Analysts
    • Investor FAQ
    • Email Alerts
    • Information Request
    • RSS Feeds

Home Home  >  News  >  Press Releases

  • Investor Relations
  • Financial Reports
    • SEC Filings
    • Annual Reports
    • Quarterly & Other Reports
  • Events & Presentations
  • Stock Information
  • Corporate Governance
    • Policies
    • Executive Officers & Directors
    • Board Committees
  • Investor Resources
    • Analysts
    • Investor FAQ
    • Email Alerts
    • Information Request
    • RSS Feeds
Normal
Press Release RSS Feed (opens in new window)
Press release year list 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002
Dec 21, 2021
Amneal to Virtually Participate at the 40th Annual J.P. Morgan Healthcare Conference
Nov 19, 2021
Amneal Receives Approval for Difluprednate Ophthalmic Emulsion
Nov 12, 2021
Amneal to Virtually Participate at Upcoming Investor Conferences
Nov 03, 2021
Amneal Reports Third Quarter 2021 Financial Results
Nov 02, 2021
Amneal Releases Inaugural Corporate Responsibility Report Highlighting Our Impact as a Socially Responsible Company
Oct 27, 2021
Amneal Launches Generic Dexamethasone Following ANDA Approval by FDA
Oct 06, 2021
Amneal to Report Third Quarter 2021 Results on November 3, 2021
Sep 07, 2021
Amneal to Virtually Participate at Morgan Stanley 19th Annual Global Healthcare Conference
Aug 25, 2021
Amneal Announces Positive Topline Results from Pivotal Phase 3 RISE-PD Clinical Trial of IPX-203 in Patients with Parkinson’s Disease Who Experience Motor Fluctuations
Aug 23, 2021
Amneal Announces Virtual Event to Discuss Initial Data from Pivotal Phase 3 Study of IPX-203 in Patients with Parkinson’s Disease Who Experience Motor Fluctuations
Aug 09, 2021
Amneal Reports Second Quarter 2021 Financial Results
Jul 19, 2021
Amneal Receives Approval for Generic TobraDex®
Jul 15, 2021
Amneal to Report Second Quarter 2021 Results on August 9, 2021
Jun 17, 2021
Amneal Announces U.S. FDA Filing Acceptance of Biologics License Application (BLA) for Bevacizumab
Jun 07, 2021
Amneal Announces Dihydroergotamine (DHE) Autoinjector NDA for Migraines and Cluster Headaches
May 14, 2021
Amneal to Virtually Participate at Upcoming Investor Conferences
May 07, 2021
Amneal Reports First Quarter 2021 Financial Results
Apr 15, 2021
Amneal to Report First Quarter 2021 Results on May 7, 2021
Apr 05, 2021
Amneal Completes Acquisition of Kashiv Specialty Pharmaceuticals
Feb 26, 2021
Amneal Receives Approval for Generic Version of Ortho Evra®
Feb 26, 2021
Amneal Reports Fourth Quarter and Full Year 2020 Financial Results
Feb 22, 2021
Amneal to Virtually Participate at Upcoming Investor Conferences
Feb 04, 2021
Amneal to Report Fourth Quarter & Full Year 2020 Results on February 26, 2021
Jan 12, 2021
Amneal to Acquire Substantially All of Kashiv Specialty Pharmaceuticals
Jan 08, 2021
Amneal Launches Generic Abiraterone Acetate Tablets, USP, 500 mg, Following ANDA Approval by FDA
Jan 05, 2021
Amneal to Virtually Participate at the 39th Annual J.P. Morgan Healthcare Conference

Investor Faq

Get answers to important investor relation questions.

More

Investor Tools

  • Email Alerts
  • RSS Feeds
  • Email Page

IR Contact

Get answers to your investor relation questions.

More
  • Privacy Policy
  • Copyright & Legal Disclaimer
  • Web Accessibility
© Amneal Pharmaceuticals LLC.
All rights reserved.
Powered By Q4 Inc. 5.86.0.1 (opens in new window)
Back to top